Littleton, Mass.-based TeraDiode, a laser manufacturer, has raised $10 million in Series B financing. Argonaut Ventures led the round, which also included participation from Camros Capital and Stata Venture Partners. The company closed its $4 million Series A round in 2009.
2 min read · 18 November 2011
Impermium, maker of a service to fight social web spam, has closed on $8 million in Series A funding. Highland Capital Partners led the round, with participation from existing investors including The Social+Capital Partnership and Freestyle Capital.
3 min read · 18 November 2011
Salt Lake City-based Healthcare Quality Catalyst Corp. has inked an undisclosed amount of financing from Sequoia Capital, and added David Burton as its chief executive. Michael Dixon, a partner at Sequoia Capital, is joining the company’s board. Formed in 2008, Healthcare Quality Catalyst is a provider of healthcare data warehousing software.
6 min read · 18 November 2011
Catalog Spree, maker of a catalog shopping app for the iPad, has sealed $6.1 million in Series A funding. Comcast Ventures led the round, with participation from BlackBerry Partners Fund and El Dorado Ventures.
3 min read · 17 November 2011
Safeguard Scientifics Inc. led a $7 million Series A round for New York-based healthcare IT company Medivo Inc. The company provides an online that which connects patients to a nationwide network of physicians, lab service centers and home testing services.
5 min read · 17 November 2011
Rapid7, a provider of security risk technology, has closed on $50 million in Series C financing from Palo Alto, Calif.-based Technology Crossover Ventures. Rapid7, which is based in Boston, will use the money to expand its product development, for potential acquisitions, and international expansion. Tim McAdam, TCV general partner, will join Rapid7’s board. The company is also backed by Bain Capital Ventures.
5 min read · 17 November 2011
Oxyrane UK Ltd., a biopharmaceutical company based in The Netherlands, has closed on $26.5 million in a equity round of funding. Investors include Forbion Capital Partners, Morningside Groups and New Science Ventures. Sander Slootweg of Forbion and Gerald Chan of Morningside Group have joined the company’s board. Oxyrane is developing enzyme replacement therapies to treat rare inheritied diseases.
4 min read · 17 November 2011
Swiss biotech start-up Biocartis has raised 71 million euro ($100 million) in Series C financing. Investors in the round include Debiopharm Group, Philips, Johnson & Johnson Development Corp., the Wellcome Trust, Korys, Valiance and Biovest. The money will be used to help commercialize the company’s compact molecular diagnostics system.
5 min read · 17 November 2011
YCharts, a maker of tools and services for stock research and analysis, has closed $3.25 million in a Series B round of financing. Morningstar Inc. led the financing with a $2.45 million investment. Existing investors Hyde Park Angels and I2A also participated.
3 min read · 17 November 2011
Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.
3 min read · 17 November 2011
